Radiolabeled Herceptin to Increase Treatment Efficacy in Breast Cancer Patients With Low Tumor HER-2/neu Expression
Abstract
The primary objective of the proposal is to evaluate the efficacy and feasibility of using radiolabeled Herceptin antibody to target rapidly accessible breast carcinoma cells or micrometastases. By using Herceptin to specifically deliver radiation we anticipate that the efficacy of Herceptin will be extended to include breast cancer cells that are not high HER-2/neu antigen expressors. This hypothesis will be tested using the spheroid model to simulate rapidly accessible micrometastases. An alpha-particle emitting radionuclide will be used to enhance tumor cell kill. Completion of tasks 1-3 and progress towards task 5 was reported in the previous annual report. The animal model previously used towards task 5 was a HER-2/neu expressing ovarian carcinoma. The PI has identified an appropriate disseminated breast carcinoma animal model and will be using this to satisfy the remaining tasks of the proposal. Because the PI relocated in 2003, progress in the past year has been delayed. The PI is in the process of setting up a sub- contract at Hopkins to complete the tasks of the proposal. The sub-contract mechanism is being used because after discussions with the contracting officer this was deemed the most expeditious approach to providing funds for the PI to complete the work at Hopkins.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA418347
Entities
People
- George Sgouros
Organizations
- Memorial Sloan Kettering Cancer Center